I

Insulet

Designs and manufactures tubeless insulin pumps

Principal Data Scientist

Full-TimePosted on 10/21/2026Deadline 1/31/27
$170.6k - $255.9k/yr+ Incentive compensation
Expert
Master's, PhD
Massachusetts, USA
HybridHybrid arrangement requires on-site work from an Insulet office.
Data & AnalyticsData Science

About the job

Requirements
  • At least 10 years of relevant professional experience in data science, statistics, econometrics, operations research, applied mathematics, machine learning, or a related quantitative discipline.
  • A demonstrated track record of providing technical leadership for complex, cross-functional analytical initiatives with material business impact.
  • Expert-level knowledge of statistical methodology, including experimental design, causal inference, regression, forecasting, Bayesian methods, and machine learning.
  • Deep proficiency in Python and modern data science libraries, including pandas, NumPy, SciPy, statsmodels, and scikit-learn.
  • Extensive experience developing and validating predictive models and supporting their transition into production environments.
  • Ability to translate ambiguous business challenges into clear analytical frameworks, decision criteria, and defensible quantitative solutions.
  • Ability to influence senior leaders and cross-functional teams through evidence, technical credibility, and clear communication.
  • Strong experience conducting technical reviews, establishing analytical standards, and mentoring experienced practitioners.
  • Hands-on experience with Databricks or a comparable cloud-based data and analytics platform.
  • Written and verbal communication skills, including the ability to explain complex quantitative concepts to non-technical audiences.
Responsibilities
  • Define and evolve analytical methodologies, standards, and best practices used across the Data Science team and broader Enterprise Data & AI organization.
  • Shape the analytical roadmap by identifying high-value opportunities, clarifying where advanced methods are warranted, and helping prioritize investments based on business value, feasibility, decision risk, and data readiness.
  • Serve as the senior technical escalation point for complex statistical, experimental, modeling, and measurement questions.
  • Provide technical direction for major cross-functional initiatives spanning multiple business domains, data products, or decision processes.
  • Evaluate emerging quantitative methods and technologies, determine their enterprise relevance, and guide responsible adoption.
  • Represent Data Science in portfolio, architecture, governance, and strategic planning forums where analytical methodology or decision quality is material.
  • Lead the design and execution of novel, high-complexity analyses supporting strategic and high-consequence decisions, and establish standards for hypothesis testing, power analysis, confidence intervals, effect-size reporting, multiple-comparison control, sensitivity analysis, and uncertainty quantification.
  • Define causal inference approaches for observational data, including difference-in-differences, regression discontinuity, propensity score methods, instrumental variables, and synthetic controls.
  • Design enterprise experimentation frameworks covering randomization, sample-size determination, holdouts, guardrail metrics, heterogeneous treatment effects, and interpretation of results.
  • Lead advanced applications of time-series analysis, forecasting, anomaly detection, survival analysis, simulation, segmentation, and optimization.
  • Determine the appropriate methodological complexity for each problem and prevent unnecessary modeling when simpler approaches are more reliable or actionable.
  • Review and approve analytical approaches for strategically significant or methodologically high-risk initiatives.
  • Define technical standards for the design, validation, explainability, monitoring, and lifecycle management of predictive and machine learning models.
  • Provide technical oversight for critical propensity, attrition, forecasting, anomaly detection, classification, regression, and optimization models.
  • Guide feature engineering, model selection, regularization, cross-validation, calibration, interpretability, fairness assessment, and robustness testing.
  • Establish performance evaluation practices balancing accuracy, calibration, stability, explainability, business utility, and operational feasibility.
  • Guide model monitoring, drift detection, retraining triggers, revalidation, and retirement criteria in partnership with AI Engineering and MLOps.
  • Ensure production-bound models include clear methodology, validation evidence, performance benchmarks, limitations, and known failure modes.
  • Partner with senior leaders and domain experts to translate ambiguous strategic challenges into analytical programs with explicit decisions, hypotheses, success measures, and value expectations.
  • Advise leaders on measurement strategy, experimentation opportunities, uncertainty, risk, and trade-offs so decisions are based on appropriate evidence.
  • Challenge unsupported assumptions and identify when available data or study design cannot reliably answer a question.
  • Recommend alternative measurement, data collection, or analytical strategies when existing evidence is insufficient.
  • Synthesize complex analyses into decision-oriented narratives without overstating certainty or obscuring limitations.
  • Connect analytical findings to practical actions, expected business impact, and measurable follow-through.
  • Establish and maintain standards for reproducible analysis, code quality, peer review, documentation, validation, and release readiness.
  • Lead independent technical reviews of high-impact analyses and models to ensure methodological soundness, traceability, and defensibility.
  • Define minimum documentation requirements for analytical methods, assumptions, data lineage, validation, limitations, sensitivity analyses, and conclusions.
  • Promote transparent reporting of uncertainty, bias, data limitations, model risk, and alternative interpretations.
  • Create reusable frameworks, libraries, templates, and reference implementations that improve consistency, speed, and quality across teams.
  • Partner with data governance, privacy, quality, and compliance stakeholders to ensure analytical work follows applicable enterprise requirements.
  • Ensure deliverables meet established Data Science and data product quality standards before release.
  • Mentor Data Scientists and Senior Data Scientists on problem framing, methodology selection, analytical design, technical communication, and career development.
  • Raise the technical bar through coaching, design reviews, code reviews, learning sessions, and communities of practice.
  • Develop reference methods and training content in experimentation, causal inference, forecasting, machine learning, and statistical reasoning.
  • Influence role expectations, hiring standards, interview practices, and technical assessment criteria for data science talent.
  • Build a culture of scientific rigor, constructive challenge, intellectual honesty, collaboration, and continuous learning.
  • Provide leadership through influence across teams without relying on direct reporting authority.
  • Partner with Insights & Analytics to align business context, analytical framing, interpretation, and decision adoption.
  • Partner with Analytics Engineering and Data Engineering to ensure analytical inputs and outputs are reproducible, governed, traceable, and accessible.
  • Partner with AI Engineering and MLOps to transition validated models into reliable production solutions with clear ownership and controls.
  • Collaborate with domain leaders and product owners to define success measures, adoption plans, and post-launch evaluation approaches.
  • Communicate methods, findings, limitations, and recommendations to executives, business stakeholders, technical peers, and governance audiences.
  • Lead or contribute to cross-functional delivery forums, technical reviews, and enterprise communities that advance responsible data science.
Desired Qualifications
  • A master's degree or PhD in statistics, mathematics, econometrics, operations research, computer science, engineering, or a related quantitative field.
  • Experience in a regulated industry such as medical devices, healthcare, pharmaceuticals, life sciences, or financial services.
  • Depth in one or more areas such as experimentation, causal inference, forecasting, survival analysis, optimization, or advanced machine learning.
  • Experience establishing analytical standards, governance practices, reusable frameworks, or enterprise data science capabilities.
  • Publications, patents, conference presentations, open-source contributions, or other evidence of external or internal thought leadership.
  • Experience advising executive leaders on strategic decisions through quantitative evidence.
  • Experience working across geographically distributed, multidisciplinary teams.

About the company

Insulet develops and manufactures insulin delivery devices for people with diabetes, led by the Omnipod tubeless, waterproof insulin pump system. The pod is worn on the body to deliver insulin under the skin, and is controlled wirelessly by a personal diabetes manager; Omnipod 5 adds automated insulin delivery that adjusts dosing using CGM data. The key differences are a tubeless, tubing-free design and ongoing updates that integrate automated dosing with CGMs, supported by a global manufacturing and distribution network. The goal is to simplify diabetes management with easy-to-use, flexible insulin delivery and automated dosing that fit users’ daily lives.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Get referred to Insulet

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $801.7 million, up 23.5% year over year.
  • International Omnipod growth guide rose to 30%-32% after Spain and broader uptake.
  • Massachusetts offered over $40 million incentives for a potential Acton expansion through 2032.

What critics are saying

  • March 12 and May 26, 2026 corrections exposed tubing defects and under-delivery risk.
  • U.S. Omnipod growth guide fell to 17%-19% after weak type 2 retention.
  • Massachusetts class action Hu v. Insulet centers on manufacturing controls; settlement pressure intensifies through 2027.

What makes Insulet unique

  • Omnipod 5 offers tubeless, waterproof AID; Spain launched July 6, 2026.
  • Abbott Libre 3 Plus integration broadens Omnipod compatibility across the UK and Europe.
  • Acton manufacturing plus U.S. headquarters keep engineering, production, and distribution tightly co-located.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%
MPO Magazine
Oct 13th, 2026
Insulet launches Omnipod Discover diabetes data platform nationwide.

Insulet launches Omnipod Discover diabetes data platform nationwide. The platform combines glucose trends, insulin delivery data, and pump settings to support treatment decisions. October 13, 2026 Associate Editor Insulet has launched its new Omnipod Discover web-based data platform for the Omnipod 5 tubeless insulin pump in the U.S. The web-based data platform is meant for Omnipod 5 users, caregivers, and healthcare professionals (HCPs). It converts diabetes data into visual reports and personalized insights to help users manage their condition and support clinical decision-making. Users receive weekly smartphone reports on glucose levels and insulin delivery, while HCPs can review an Ambulatory Glucose Profile alongside pump settings and bolus events to guide treatment recommendations. During its limited U.S. release, the platform was adopted by more than 15,000 Omnipod 5 users and 1,800 HCPs. It is also available in Spain, Australia, Saudi Arabia, Qatar, Kuwait, the United Arab Emirates, and Israel. At the American Diabetes Association's Scientific Sessions in June, Insulet presented real-world data associating platform use with improved time in range (TIR). Thirty-two percent of users achieved a clinically meaningful TIR increase of at least 3%. Omnipod Discover is now available nationwide to Omnipod 5 users. HCPs can enroll through onboarding and training with their dedicated Omnipod sales representative. Last month, the company appointed former Philips Healthcare exec Jonathan ("Jay") Mazelsky to its board of directors. Dr. Trang Ly, MBBS, FRACP, Ph.D., senior VP and chief medical officer at Insulet: "The future of diabetes care is not just about generating more data, it's about making that data meaningful. Omnipod Discover simplifies data review for Omnipod 5 users and their healthcare providers so they spend less time gathering information and more time collaborating on diabetes management." Dr. Martin Sarkar, DO, ECNU, endocrinologist at EndoCARE Diabetes & Wellness Center: "In today's AID (automated insulin delivery) era, clinicians need actionable insights, not more data. Omnipod Discover brings key diabetes metrics and insights together in a streamlined, easy-to-use workflow that supports clinical decision-making and patient conversations. It also gives people with diabetes greater visibility into their therapy, helping foster engagement and trust. Omnipod Discover is an important step toward a more connected diabetes ecosystem that supports both providers and patients." Add Mpo Mag as a preferred source on Google. Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Yahoo Finance
Oct 12th, 2026
Insulet launches Omnipod Discover in the US, already used by over 15,000 Omnipod 5 users

Insulet Corporation has released Omnipod Discover across the US. The web-based data platform turns Omnipod 5 insulin pump data into clear visuals and personalised insights for users, caregivers, and healthcare professionals. Users get weekly glucose and insulin delivery reports on their smartphones. Clinicians get a concise report that overlays an Ambulatory Glucose Profile with key pump settings and bolus events. More than 15,000 Omnipod 5 users and over 1,800 healthcare professionals used the platform during a limited US release. It is also available in Spain, Australia, Saudi Arabia, Qatar, Kuwait, the UAE, and Israel. In data presented in June, 32% of users saw a clinically meaningful increase of 3% or more in time in range.

Boston Real Estate Times
Sep 11th, 2026
Insulet weighs major Acton expansion as state offers $40M in incentives.

Insulet weighs major Acton expansion as state offers $40M in incentives. September 11, 2026 ACTON - Massachusetts is offering Insulet Corp. a record-setting package of tax incentives as the medical device company considers expanding its operations and workforce in Acton, according to reporting by the Boston Business Journal. The proposed package from the Massachusetts Life Sciences Center would provide Insulet with at least $40,000 in tax credits for each new job created, up to 1,000 net new permanent full-time positions through 2032. The potential incentives would total more than $40 million, making it the largest single-company package offered through the state's life sciences tax incentive program, the Business Journal reported. Insulet, which is headquartered in Acton and makes automated insulin delivery systems under its Omnipod brand, is evaluating additional space near its existing campus as it continues to grow. The company has more than 1,700 employees in Massachusetts and has added more than 200 positions in the state this year, according to the Business Journal. "As employee growth has increased the need for collaboration and on-site engagement, the company is actively evaluating additional space in the Acton area," Insulet spokesperson Joan Campion told the Business Journal. The company is considering taking over 35 Nagog Park, a property near its global headquarters and U.S. manufacturing facility at 100 Nagog Park. Insulet also leases space at 50 Nagog Park, which serves as a distribution center. According to documents reviewed by the Business Journal, Insulet is considering spending about $33 million to renovate 35 Nagog Park into Class A office space with capacity for roughly 500 to 530 employees. The company has also outlined an additional $11 million to $12 million investment at 100 Nagog Park to enhance its UPS capabilities and add approximately 250 seats. If both projects move forward, the company's seating capacity in Acton would more than double from its current level of about 650, according to the Business Journal. The potential expansion has received support from Acton officials. Town Meeting voters approved a tax increment financing agreement for the 6.54-acre property at 35 Nagog Park earlier this year. The agreement is intended to support redevelopment of the property, although final terms have not yet been completed. The state effort to retain Insulet began in earnest in late 2025 as company officials explored options for expanding its manufacturing footprint. According to public records obtained by the Business Journal, state officials worked with Insulet on potential sites and offered assistance with real estate, local governments, financing, tax incentives and workforce development under the code name "Project Maverick." Massachusetts officials have characterized the potential expansion as an opportunity to retain a growing medical device company and create hundreds of additional jobs. Gov. Maura Healey told the Business Journal that the administration wants innovative companies to continue expanding in Massachusetts. "Massachusetts is where some of the world's most innovative companies are born, and we want them to build their future here too," Healey said, according to the Business Journal. "Insulet's expansion means hundreds of good jobs, new opportunities for our residents and continued investment in the communities that make our economy strong." Insulet has not yet made a final decision on its expansion plans. Campion told the Business Journal that the documents reflect preliminary planning and evaluation, including assessments of future operational and manufacturing needs. She said no definitive lease or purchase agreements have been executed and no final decisions have been made. Founded in 2000, Insulet has remained headquartered in Massachusetts as it has grown into a major medical device company. The company reported $2.7 billion in revenue in 2025 and had a global workforce of approximately 5,400, according to the Boston Business Journal. The potential expansion would build on an earlier expansion of Insulet's Acton operations. The company moved its global headquarters and U.S. manufacturing operations to 100 Nagog Park in 2019 following a redevelopment supported by a previous local tax incentive agreement. Acton Town Meeting approved the latest TIF proposal for 35 Nagog Park by a vote of 242 to 18, according to local records. The latest state incentive offer underscores the competition among states and communities to retain growing life sciences and advanced manufacturing companies and the jobs and investment they bring. This article is based on reporting by the Boston Business Journal. The Business Journal's full report was published Sept. 8, 2026, by reporter Hannah Baratham-Green.

The Diabetes Times
Sep 10th, 2026
Abbott's Libre established as the "most connected CGM in the world"

Abbott's Libre established as the "most connected CGM in the world" 10th September 2026 Abbott today announced the integration of its FreeStyle Libre 3 Plus sensor with Insulet's Omnipod(R) 5 Automated Insulin Delivery (AID) System in the UK, further expanding connected care options for people living with Type 1 diabetes who use a Libre sensor. The full UK availability of this latest integration builds on Abbott's FreeStyle Libre 3 Plus sensor and Tandem Diabetes Care's t:slim X2 insulin pump integration, which became available this summer. Based on the number of pump users having the ability to connect with Libre technology globally these latest partnerships establish Libre as the most connected continuous glucose monitoring (CGM) technology in the world*, providing users with access to more pump options globally than any other CGM. Today, in the UK, Abbott's connected diabetes management solutions are compatible with the following automated insulin delivery systems, or insulin pumps: * Insulet's Omnipod(R) 5 with both the FreeStyle Libre 3 Plus and the FreeStyle Libre 2 Plus sensors * Tandem Diabetes Care's t:slim X2 insulin pump with the FreeStyle Libre 3 Plus sensor * mylife Diabetes Care's YpsoPump insulin pump with the FreeStyle Libre 3 Plus sensor * MiniMed(TM) 780G system with the Instinct sensor, made exclusively by Abbott and distributed by Medtronic Hybrid closed loop systems like these combine a CGM with an insulin pump to automatically adjust insulin delivery based on glucose readings. They help people spend less time managing their condition and more time focusing on the things that matter to them. Libre technology provides real-time, personalised insights to help people understand how food, activity and medications affect their bodies. The latest Libre innovation is the world's first dual glucose-ketone sensor, which monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis, a serious diabetes-related complication. Graeme Scott, 58, from Angus, who lives with type 1 diabetes said: "My life has changed immensely for the better since starting on a hybrid closed loop system. Having my sensor and pump working together gives me greater confidence and flexibility day-to-day, helping reduce the burden of managing diabetes. The technology means I spend less time thinking about my glucose levels and more time focusing on the things I enjoy. I'm running my own life instead of letting diabetes run it for me." Julia Hammac, General Manager for Abbott's diabetes care business in the UK, said: "For people living with type 1 diabetes, having access to technologies that work seamlessly together can make a meaningful difference to day-to-day diabetes management. By expanding our hybrid closed loop partnerships, we're giving people more choice in how they manage their condition and helping make advanced diabetes technologies more accessible through connected care solutions." Hilary Nathan, Director of Policy and Communications at Breakthrough T1D said: "For many people living with type 1 diabetes, technology is part of everyday life. Having choice really matters. Everyone's experience of diabetes is different, and what works brilliantly for one person may not be right for another. We welcome developments that give people more options and greater flexibility in how they manage their condition, allowing them to choose technology that fits their individual needs, preferences and lives. Ultimately, we want to see a technology landscape shaped around the people who use it, with the freedom to choose the tools that work best for them and today's announcement helps us take one step further towards that." *Data on File, Abbott Diabetes Care

Yahoo Finance
Sep 4th, 2026
Insulet beats Q2 estimates with $801.7M revenue, up 23.5% year on year

Insulet reported second-quarter revenues of $801.7 million, up 23.5% year on year and exceeding analyst expectations by 1.9%. The diabetes care company, which makes tubeless insulin delivery systems, posted the fastest revenue growth among four patient monitoring stocks tracked. However, Insulet's revenue guidance for the next quarter significantly missed analyst expectations. Despite beating earnings per share estimates, the market reacted negatively to the results. The stock has fallen 11.6% since the earnings announcement and currently trades at $147.50. The patient monitoring sector posted strong second-quarter results overall, with revenues beating consensus estimates by 1.4% across the group. Share prices for the four companies tracked have risen 2% on average since reporting earnings.